Summary:
CenExel CIT is currently enrolling in an inpatient schizophrenia study. "A Placebo-controlled Trial of 15 and 30 mg QD Doses of CVL-231 in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis"
Criteria:- 18 - 65 Years Old
- Diagnosis of Schizophrenia at least 1 year.
- Insurance is not required to qualify.
- Currently experiencing symptoms of schizophrenia
Qualified Participants May Receive:
- Compensation for each visit and study-related treatment.
- Investigational medications at no cost.